Oric Pharmaceuticals (ORIC) Non-Current Deffered Revenue (2019 - 2020)
Oric Pharmaceuticals (ORIC) posted Non-Current Deffered Revenue of $219000.0 for Q4 2020, down 39.0% on a QoQ basis from $359000.0 in Q3 2020, and down 71.37% year-over-year from $765000.0 in Q1 2020.
Oric Pharmaceuticals (ORIC) Non-Current Deffered Revenue (2019 - 2020) Analysis & Trends
Oric Pharmaceuticals' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $219000.0 for Q4 2020.
- Quarterly Non-Current Deffered Revenue fell 71.37% year-over-year to $219000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $219000.0 (down 71.37% YoY) and the FY2020 annual result came in at $219000.0, down 71.37% from the prior year.
- Non-Current Deffered Revenue was $219000.0 for Q4 2020 at Oric Pharmaceuticals, down from $359000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $765000.0 in Q4 2019 and bottomed at $219000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Oric Pharmaceuticals | 1.15 Bn | 866.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 219,000.00 |
| Sep 30, 2020 | 359,000.00 |
| Jun 30, 2020 | 500,000.00 |
| Mar 31, 2020 | 635,000.00 |
| Dec 31, 2019 | 765,000.00 |